
Elevation Oncology, Inc. (NASDAQ:ELEV) received Fast Track designation from the Food and Drug Administration (FDA) for Seribantumab in tumor-agnostic settings for the treatment of advanced solid tumors that harbor NRG1 gene fusions.
Seribantumab is being investigated in the ongoing Phase 2 CRESTONE study for patients with solid tumors harboring NRG1 gene fusions.